In a breakthrough finding, revealed through the final analysis of a mid-stage trial, Japanese pharmaceutical firm, Eisai Co and Biogen Inc’s drug for Alzheimer’s proved beneficial for patients who received the highest dose.
EIP Pharma raised $20.5 million series B funding to support Neflamapimod, the phase 2b program of its Alzheimer treatment. The funding is also to build the team and to support other research studies related to central nervous system disorders.
Washington University School of Medicine sleep specialist Yo-El Ju, MD, led a research team that found circadian rhythm disruptions occur in people whose memories are intact but whose brain scans show early, preclinical evidence of Alzheimer's disease. She previously had discovered that people with clinical symptoms of Alzheimer's have disturbances in their internal body clocks that affect the sleep/wake cycle. Credit: Washington University School of Medicine.
Amgen and Basel, Switzerland-based Novartis announced they have expanded their collaboration with the Banner Alzheimer’s Institute (BAI) to launch a new clinical trial in Alzheimer’s.
Buildups of "clumpy" proteins in the brain are well-known hallmarks of Alzheimer's, but not everyone who has them goes on to develop this neurodegenerative disease. Why is that? New research investigates.
AbbVie (ABBV), a global biopharmaceutical company, and Alector, a privately owned biotechnology company, announced a global strategic collaboration to develop and commercialize medicines to treat Alzheimer's disease and other neurodegenerative disorders.
The future of researching ways to prevent AD should probably focus on people at risk for developing the disease, said researchers, and should highlight how to improve management of chronic health conditions and education about living healthier.
In 2021, neurological conditions, including Alzheimer’s disease, affected approximately 3.4 billion people globally In a new study funded by the Bill & Melinda Gates Foundation, results published in the Lancet Neurology have determined that neurological conditions are currently the leading cause of ill health worldwide. Results showed that the biggest contributors to neurological health loss globally were stroke, neonatal encephalopathy, migraine, Alzheimer’s disease and other dementias, and diabetic neuropathy. Affecting 3.4 billion people globally in 2021, neurological conditions are any conditions that affect the brain, spinal cord and nerves, which can affect anyone at any age. The study revealed that the number of people globally living with or dying from neurological conditions has drastically risen in the past three decades, partially due to ageing societies. Worldwide, the analysis suggests that the total amount of disability, illness and premature death caused by neurological conditions increased by 18% between 1990 and 2021. ...
March 4), according to the CDE official website, Lundbeck’s clinical trial application for Class 1 chemical drug Lu AF28996 capsules has been accepted. Currently, the drug is undergoing Phase I clinical trials overseas. Parkinson’s disease is a neurological dysfunction disease with complex symptoms and difficult early diagnosis. It is common in middle-aged and elderly people. At present, the main treatment for Parkinson’s disease is drug therapy, with the purpose of reducing symptoms, delaying the progression, and improving the patient’s quality of life. Lu AF28996 is a dopamine D1/D2 receptor agonist developed by Lundbeck Pharmaceuticals. It is a relatively new anti-Parkinson therapy and is currently undergoing Phase I clinical trials overseas. Among them, a study to evaluate the safety, tolerability, etc. of Lu AF28996 in Parkinson’s patients is expected to be completed in 2025. This time, the approval of Lu AF28996’s clinical trial application in China is expected to bring a ...
Alzheimer’s disease, which traditionally requires costly scans or invasive spinal taps for diagnosis, is now closer to being more easily identified through innovative blood tests. This advancement is particularly crucial with the recent approval of disease-modifying treatments for Alzheimer’s. Now, the results of a study have shown how new Alzheimer’s detecting blood tests perform across a broad range of races and ethnicities for the first time. The Global Alzheimer’s Platform Foundation (GAP, Washington, DC, USA) is releasing the first results from the Bio-Hermes-001 Study. To address diagnostic challenges in Alzheimer’s disease, GAP formed a unique coalition of top biopharma, digital technology firms, nonprofit partners, and 17 clinical research sites from the GAP network (GAP-Net) across the US for the Bio-Hermes study. Conducted with over 1,000 participants from various US communities, the study compared blood and digital biomarker results with brain amyloid PET scans and cerebrospinal fluid assays. The study found ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.